Are symptoms of obstructive sleep apnoea syndrome related to bronchitic symptoms or lung function impairment? Report from the obstructive lung disease in Northern Sweden study  by Larsson, L-G. et al.
RESPIRATORY MEDICINE (1998) 92, 283-288 
Are symptoms of obstructive sleep apnoea 
syndrome related to bronchitic symptoms or lung 
function impairment? Report from the Obstructive 
Lung Disease in Northern Sweden Study 
L-G. LARSSON*+, B. LLJNDB;~CK+*, E. J~NSSON*, A. LINDBERG”+ AND 
T. SANDSTROM*’ 
“Department of Respiratory Medicine, Central Hospital of Norrboften, lule&Boden, Sweden 
‘OLIN Study Group, Central Hospital of Norrboffen, Luleb-Boden, Sweden 
*National Institute for Working Life, Deparfmenf of Occupational Health, Respirafory Epidemiology 
Unit, University Hospital of Northern Sweden, UrneQ Sweden 
‘Department of Pulmonary Medicine and Allergy, Universify Hospital of Northern Sweden, Umei, 
Sweden 
To investigate whether the high prevalence of symptoms related to obstructive sleep apnoea syndrome (OSAS) in a 
bronchitic cohort is correlated with the bronchitic symptoms or lung function impairment we examined two cohorts 
with bronchitic symptoms (n=357 and 82) and a reference group who had reported no respiratory symptoms in a 
previous survey in 1986 (n= 140). The study was a part of the Obstructive Lung Disease in Northern Sweden Study 
and included clinical examination and lung function tests. 
Although lung function measured as FEV, percentage predicted was correlated with bronchitic symptoms we 
found that bronchitic symptoms and body mass index but not lung function impairment were correlated with 
symptoms related to obstructive sleep apnoea. 
According to our findings it was the various bronchitic symptoms such as longstanding cough, wheezing, sputum 
production and chronic productive cough that were correlated with OSAS symptoms. This might be due to increased 
upper airway swelling or increased upper airway resistance, and lung function impairment does not seem to be 
responsible for the high prevalence of symptoms related to obstructive sleep apnoea in this bronchitic cohort. 
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Introduction 
In a postal survey, subjects with various bronchitic symp- 
toms reported symptoms related to the upper airway resist- 
ance syndrome (UARS) or the obstructive sleep apnoea 
syndrome (OSAS) more frequently than subjects without 
respiratory complaints (1). Similar results have recently 
been reported (24). 
Subjects with chronic bronchitis, chronic obstructive 
pulmonary disease and concomitant OSAS are thought to 
have more severe disease with deeper and more prolonged 
oxygen desaturations and may be more likely to develop 
pulmonary hypertension (5-9). The mechanism behind this 
higher prevalence of snoring, apnoea and other symptoms 
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believed to be related to OSAS among bronchitic subjects is 
not known. There are several possible factors that could 
be responsible for this high interrelationship, including 
inflammatory swelling of the upper airways, excessive 
sputum production or lung function impairment that often 
occurs in bronchitic subjects. 
The epidemiological survey the Obstructive Lung Disease 
in Northern Sweden Study (OLIN) started as a cross- 
sectional study designed to estimate the prevalence of 
obstructive airway diseases (10,ll) and to be the starting 
point for longitudinal studies (12). Within this project, we 
made a postal questionnaire survey of symptoms related 
to UARS or OSAS and bronchitic symptoms in a 
population cohort with chronic bronchitis and bronchitic 
symptoms. This cohort also underwent clinical examination 
and lung function tests. The aim of this study was 
to examine whether the expected high prevalence of 
symptoms related to OSAS was related to the bronchitic 
symptom or to lung function impairment in a bronchitic 
cohort. 
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TABLE 1. Subjects invited and participants in the bronchitic 
and the two reference groups by sex 
Male Female Total 
Bronchitic group 
Invited 
Drop outs 
Participants 
RS group 
Invited 
Drop outs 
Participants 
RR group 
Invited 
Drop outs 
Participants 
279 171 
62 31 
217 (78%) 140 (82%) 
69 39 108 
18 8 26 
51 (74%) 31 (79%) 82 (76%) 
115 63 178 
24 14 38 
91 (79%) 49 (78%) 140 (79%) 
450 
93 
357 (79%) 
Participant percentages are with respect to the number 
invited. RS, not randomized from the reference group 
but with bronchitic symptoms in the questionnaire. RR, 
stratified sample from the reference group. 
Material and Methods 
STUDY POPULATION 
The first part of the OLIN project was a prevalence study 
performed in 19861987 in which all 6610 adults from 
representative geographical areas in northern Sweden born 
in 1919-1920, 19341935 and 1949-1950 were screened for 
airway diseases (11,12). In 1991 a further questionnaire 
designed to elicit respiratory symptoms and symptoms 
related to OSAS was sent to respondents in the 1986 survey 
who had reported bronchitic disease (n=523) and to a 
reference group (1) made up of a stratified sample of 
subjects without respiratory complaints in the previous 
study (n=625). All subjects from the bronchitic group (B) 
that answered the questionnaire (n=450), a random sample 
after stratification by age and sex from the reference group 
(RR) (n=178) and all subjects from the questionnaire- 
reference group that reported bronchitic symptoms (RS) in 
the second questionnaire (n= 108) were invited to this study. 
The subjects in the RS group were included because they 
had bronchitic symptoms of shorter duration than the 
subjects in the bronchitic group. 
In the bronchitic group, 357 subjects (79%) out of 450 
participated. The corresponding figures in the random 
reference group (RR) were 140 (79%) out of 178, and for 
the symptomatic reference group (RS), 82 (76%) out of 108. 
The study population and the participants in this study are 
shown in Table 1. 
METHODS 
A clinical examination, a structured interview and lung 
function tests were performed by two specially trained 
nurses. The interview included questions about respiratory 
symptoms, smoking habits and questions related to UARS 
or OSAS. Lung function tests were performed with a dry 
spirometer (Mijnhard Vicatest 5). Swedish reference values 
reported by Berglund et al. (13) were used. 
The questions about symptoms related to OSAS were as 
follows: 
l Do you snore so much that you think it is a problem? 
l Have relatives expressed worry about you stopping 
breathing while you are asleep? 
l Do you feel completely rested after a full night’s sleep? 
l Do you nod off during breaks in daytime activities? 
In the results and in the tables, the third question is 
reported in an inverse way (i.e. percentages of subjects who 
were not fully rested). 
The respiratory symptoms and conditions used in the 
analyses were: 
l long-standing cough, 
l sputum production, 
l recurrent wheeze, and 
l chronic productive cough. 
Chronic productive cough was defined as cough and 
sputum production on most days in periods of at least 3 
months for at least two successive years. The definition 
follows the CIBA Guest Symposia criteria (14) 
ANALYSIS 
Statistical analyses were performed using the Statistical 
Package for the Social Sciences (SPSS). 
Symptoms related to sleep disorders are expressed: 
l as crude prevalence rates in the bronchitic and the 
reference groups, and 
l in relation to age, sex, smoking habits, respiratory symp- 
toms and in relation to FEV, percentage of predicted 
value and body mass index (BMI). 
Multiple logistic regression analysis was used to assess the 
simultaneous influences of possible factors on symptoms 
related to UARS and OSAS. Fisher’s two-tailed exact test 
was used to analyse differences between OSAS symptoms in 
subjects with various bronchitic symptoms. FEV, was 
analysed in relation to bronchitic and OSAS-related symp- 
toms in the whole study population in order to enhance the 
relationship. 
Results 
PREVALENCE RATES OF RESPIRATORY 
SYMPTOMS 
Table 2 shows the distribution of respiratory symptoms in 
the bronchitic and the two reference groups. The most 
common bronchitic symptom in the bronchitic group was 
long-standing cough (89%), followed by sputum production 
(82%) and recurrent wheeze which was reported by 67%. 
TABLE 2. Distribution of respiratory symptoms in percent in 
the bronchitic group (B) and the two reference groups 
Group Percentage 
Long-standing cough 
Sputum production 
Chronic productive cough 
Recurrent wheeze 
At least one symptom 
At least two symptoms 
At least three symptoms 
All four symptoms 
B 89 
RS 73 
RR 41 
B 82 
RS 60 
RR 29 
B 14 
RS 35 
RR 14 
B 67 
RS 48 
RR 26 
B 94 
RS 19 
RR 51 
B 87 
RS 66 
RR 34 
B 71 
RS 48 
RR 17 
B 55 
RS 23 
RR 8 
RS, not randomized from the reference group but with 
bronchitic symptoms in the questionnaire. RR, stratified 
sample from the reference group. 
Symptoms were also common in the RS group. In the RR 
group, long-standing cough was reported by 41% of 
respondents. In the bronchitic group, chronic productive 
cough was reported by 74%, and by 35% in the RS group 
and 14”/0 of respondents in the RR group. All four bron- 
chitic symptoms were reported by 55% in the bronchitic 
group, by 23% in the RS group and by 8% in the RR group. 
There were no age and sex differences in these prevalence 
figures. 
PREVALENCE RATES OF SYMPTOMS RELATED 
TO SLEEP DISTURBANCES 
The most common symptom in all groups was not being 
fully rested on awakening and was reported by 31% of 
respondents in the bronchitic, 23% in the RS and 18% in the 
RR groups. The corresponding figures for snoring were 18, 
15 and 11% and for apnoea 13, 11 and lo%, respectively. 
Liability to nodding off was reported by 9% of respondents 
in the bronchitic group, by 11% in the RS group and by 3% 
in the RR group. At least one OSAS-related symptom was 
reported by 47% in the bronchitic group, by 39% in the RS 
group and by 28% in the RR group. The corresponding 
figures for at least three symptoms were 7, 6 and 4% 
respectively. In the three groups, all four symptoms were 
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reported by l-2%. The most common combination of three 
OSAS-related symptoms was snoring, apnoea and not 
being rested on awakening, which was reported by 3-5% in 
the different groups. 
Subjects who reported any of the bronchitic symptoms 
also reported symptoms related to OSAS more frequently 
as shown in Table 3. Snoring was reported by 20% of 
subjects with chronic productive cough compared with 11% 
of those who did not report chronic productive cough. The 
corresponding figures were respectively 16 KS. 7”/0 for 
apnoea, 31 rs. 21% for not being rested and 13 vs. 3% for 
liability to nod off. The proportions of OSAS-related 
symptoms were similar in those subjects who had reported 
long-standing cough, sputum production and recurrent 
wheeze. 
LUNG FUNCTION, FEV, AND BMI IN 
RELATION TO RESPIRATORY SYMPTOMS AND 
SYMPTOMS RELATED TO SLEEP 
DISTURBANCES 
As shown in Table 3, lung function measured as FEV, and 
expressed as a percentage of the predicted value was 
significantly lower in subjects who reported any of the 
bronchitic symptoms. For subjects with recurrent wheeze 
FEV, percentage of the predicted value was 88% compared 
with 98% for those who did not report the symptom. 
Corresponding values for chronic productive cough were 89 
rs. 97%, for long-standing cough 91 vs. 98% and for sputum 
production 91 1’s. 100%. 
Subjects who reported bronchitic symptoms in 1986 had 
significantly lower FEV, than subjects who only had 
bronchitic symptoms in the 1991 survey. For subjects with 
at least one bronchitic symptom, FEV, was 90 vs. 95% 
(P=O.O15). The figures for the different bronchitic 
symptoms were similar. 
As shown in Table 3, subjects with recurrent wheeze were 
slightly but significantly heavier (BMI 26 vs. 25 kg m ~ ‘). 
The same was true for those with chronic productive cough, 
BMI 26 vs. 25 kg m - 2). For subjects with long-standing 
cough and sputum production there was no significant 
difference in BMI. Subjects who reported snoring, apnoea 
or liability to nod off were heavier with BMI 27 rs. 
25 kg m ~ 2 (Table 4). No difference in BMI was seen for 
those who reported that they were not rested after a full 
night’s sleep. 
As shown in Table 4, FEV, as a percentage of the 
predicted value was 93% for both snorers and non-snorers. 
The same values were found in those with apnoea. Subjects 
who reported liability to nod off had an FEV, percentage of 
the predicted value of 94 vs. 93% for those who did not 
report the symptom. Corresponding values for being not 
rested after a full night’s sleep were 91 vs. 94%. There was 
no correlation between FEV, percentage of the predicted 
value and OSAS-related symptoms. 
Using multiple logistic regression analysis, the only 
factors that consistently were independently correlated with 
OSAS symptoms were BMI and the various bronchitic 
symptoms. 
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TABLE 4. BMI and FEV, in relation to OSAS symptoms, showing differences (P values) between 
subjects with and without symptoms related to OSAS or UARS 
Answer 
BMI 
(kg m ~ ‘) P value 
FEV, 
(% of predicted) P value 
Snoring Yes 26.5 0.004 93 0.841 
No 25.3 93 
Apnoea Yes 26.1 0.004 93 0.892 
No 25.3 93 
Not rested Yes 25.3 0.526 91 0.089 
No 256 94 
Nodding off Yes 27.1 0.003 94 0.588 
No 25.4 93 
Discussion 
The aim of this study was to examine whether symptoms 
related to OSAS were related to lung function impairment 
or only to the various bronchitic symptoms in a bronchitic 
cohort. The great majority of the subjects in the bronchitic 
group who had reported bronchitic symptoms in 1986, 
had these symptoms at the second survey in 1992. Only 
6% reported no bronchitic symptoms this time. The 
follow-up study shows clearly that chronic bronchitis 
really is a chronic condition. The prevalence of bronchitic 
symptoms in the random reference group (RR) indicates a 
high incidence of these symptoms. In the random reference 
group the prevalence of respiratory symptoms was 
similar to that in the general population in northern 
Scandinavia (12,15). 
The validity of this study is dependent on the study 
population and the methods used to investigate the aim of 
the study. The study cohort is based on a population study 
and thus representative for bronchitis in the community. 
Further, the bronchitic cohort is large, stable and well 
defined (12). Concerning methods, most questionnaires and 
interview studies in OSAS have focused on, and some have 
tried to quantify, snoring (16-18). We wanted to identify 
subjects that experience their sleep disturbances as a prob- 
lem. Although questions about snoring and apnoeas are 
used as screening for OSAS one cannot equate these 
symptoms with the syndrome OSAS (l&19). However, we 
know that there is a correlation between those symptoms 
and OSAS (16-19) and that the symptoms are symptoms of 
OSAS (20). 
As expected, FEV, was significantly lower in subjects 
with bronchitic symptoms. The duration of bronchitic 
symptoms correlated with FEV,; subjects with bronchitic 
symptoms in the bronchitic group had lower FEV, than 
subjects with the same bronchitic symptoms in the two 
reference groups; the longer the duration of bronchitic 
symptoms, the more pronounced the lung function 
impairment. 
In this bronchitic cohort, the prevalence of OSAS-related 
symptoms was high. Confirming the results from the ques- 
tionnaire survey (1) symptoms related to OSAS were 
significantly more common in subjects with bronchitic 
symptoms and this study indicates a higher prevalence of 
symptoms related to OSAS in subjects with chronic bron- 
chitis and other bronchitic symptoms, results supporting 
those of other studies (2-4). 
In chronic bronchitis bronchial obstruction could be 
caused mainly by reduced elastic recoil, airway collapsibil- 
ity or by inflammatory bronchial swelling (21). If inflam- 
mation and sputum production are the main feature of 
bronchitis, one could expect that increased resistance 
should affect at least the lower and possibly the upper 
respiratory tract and give reduction in FEV, and increase 
symptoms related to OSAS. In this study, it was the 
bronchitic symptoms and not the lung function impairment 
that correlated with OSAS symptoms. Inflammatory swell- 
ing and sputum production may contribute to OSAS- 
related symptoms in bronchitic subjects. Further, an 
intrathoracic airflow limitation might give less inspiratory 
airflow in the upper airways and hence less negative pres- 
sure and less tendency to produce upper airway obstruc- 
tion. Studies of FIV might contribute to new knowledge in 
this field. The findings of our study are in accordance with 
our clinical experience that it is the ‘blue bloaters’ that have 
OSAS, not the ‘pink puffers’; however, these aspects have 
not been discussed in the literature. 
In this study we could find no relation between smoking 
habits and OSAS symptoms, but this study was not 
designed to investigate the role of smoking and smoking is 
probably a major confounding factor in this bronchitic 
cohort, making study of its role in OSAS symptoms in this 
cohort impossible. 
BMI did not uniformly differ between bronchitic and 
non-bronchitic subjects; the difference was small. Subjects 
with symptoms related to OSAS were slightly but signifi- 
cantly heavier except for the symptom not being rested, 
which we believe is the symptom where other sleep- 
disturbing diseases, such as chronic bronchitis, contribute 
most. 
In conclusion, of the investigated factors, bronchitic 
symptoms, BMI, smoking and FEV,, only bronchitic symp- 
toms and, as expected, BMI correlated with symptoms 
related to OSAS. Thus it is important to perform sleep 
studies in bronchitic subjects presenting symptoms related 
to OSAS, even when lung function is not affected. 
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